Assay for Hepatitis B Core-related Antigen Identify Patients With High Viral Load: Systematic Review and Meta-analysis of Individual Participant Data
- Yoshida, Kyoko
- Desbiolles, Alice
- Feldman, Sarah
- Ahn, Sang Hoon
- Alidjinou, Enagnon
- Atsukawa, Masanori
- Bocket, Laurence
- Brunetto, Maurizia
- Buti, Maria
- Carey, Ivana
- Caviglia, Gian Paolo
- Chen, En-Qiang
- Cornberg, Markus
- Enomoto, Masaru
- Honda, Masao
- zu Siederdissen, Christoph Höner
- Ishigami, Masatoshi
- Janssen, Harry La
- Maasoumy, Benjamin
- Matsui, Takeshi
- Matsumoto, Akihiro
- Nishiguchi, Shuhei
- Riveiro-Barciela, Mar
- Takaki, Akinobu
- Tangkijvanich, Pisit
- Toyoda, Hidenori
- van Campenhout, Margo Jh
- Wang, Bo
- Wei, Lai
- Yang, Hwai-I
- Yano, Yoshihiko
- Yatsuhashi, Hiroshi
- Yuen, Man-Fung
- Tanaka, Eiji
- Lemoine, Maud
- Tanaka, Yasuhito
- Shimakawa, Yusuke
DOIAbstract
International audienceScale-up of tests and treatments is needed to eliminate hepatitis B virus (HBV) infection from resource-limited countries. However, access to nucleic acid tests that quantify HBV DNA, to determine treatment eligibility, is severely limited. We performed a systematic review and meta-analysis to assess the performance of the hepatitis B core-related antigen (HBcrAg) immunoassay, a low-cost (less than $15/assay) alternative to the nucleic acid test, to identify highly viremic patients, infected with any HBV genotype
Add to ORKG